GlobeNewswire Inc | Jul 20, 2020 04:01PM EDT

July 20, 2020

Montrouge, France, July 20, 2020

AMF REGULATED INFORMATION

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

As of June 30, 2020, the following assets appeared on the liquidity account:

-- 53,101 DBV Technologies ordinary shares; -- 393,440.80

As of July 8, 2018, upon signing of the liquidity contract, the following resources appeared on the liquidity account:

-- 24,313 DBV Technologies ordinary shares; -- 682 454,94

Number of transactions executed during the first half-year 2020:

-- Purchase: 1,451 -- Sale: 1,373

Over the same period, the volumes traded represented:

-- 332,424 DBV Technologies ordinary shares purchased for 4,464,245.8 -- 288,323 DBV Technologies ordinary shares sold for 3,806,200.4

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut (DBV712). DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Contact Sara Blum ShermanSenior Director, Investor Relations & Strategy+1212-271-0740sara.sherman@dbv-technologies.com

Attachment

-- PDF Version